<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Can Liver J</journal-id><journal-id journal-id-type="iso-abbrev">Can Liver J</journal-id><journal-id journal-id-type="pmc-domain-id">4219</journal-id><journal-id journal-id-type="pmc-domain">canlivj</journal-id><journal-id journal-id-type="publisher-id">canlivj</journal-id><journal-title-group><journal-title>Canadian Liver Journal</journal-title></journal-title-group><issn pub-type="epub">2561-4444</issn><publisher><publisher-name>University of Toronto Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11089472</article-id><article-id pub-id-type="pmcid-ver">PMC11089472.1</article-id><article-id pub-id-type="pmcaid">11089472</article-id><article-id pub-id-type="pmcaiid">11089472</article-id><article-id pub-id-type="pmid">38746863</article-id><article-id pub-id-type="doi">10.3138/canlivj-2023-0016</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>&#8216;<italic toggle="yes">I just never wanted them to feel uncomfortable</italic>&#8217;: Barriers to pharmacy-based identification and treatment of hepatitis C in Victoria, Canada</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Selfridge</surname><given-names initials="M">Marion</given-names></name><degrees>PhD</degrees><role content-type="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-original-draft">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-review-&amp;-editing">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barnett</surname><given-names initials="T">Tamara</given-names></name><degrees>BScN</degrees><role content-type="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-original-draft">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-review-&amp;-editing">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lundgren</surname><given-names initials="K">Karen</given-names></name><degrees>BScN</degrees><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-review-&amp;-editing">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guarasci</surname><given-names initials="K">Kellie</given-names></name><degrees>BScN</degrees><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-review-&amp;-editing">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Drost</surname><given-names initials="A">Anne</given-names></name><degrees>BScN</degrees><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-review-&amp;-editing">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fraser</surname><given-names initials="C">Chris</given-names></name><degrees>MD</degrees><role content-type="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/investigation">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-original-draft">Writing &#8211; original draft</role><role content-type="https://credit.niso.org/contributor-roles/writing-&#x2013;-review-&amp;-editing">Writing &#8211; review &amp; editing</role><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label><sup>1</sup></label>Cool Aid Community Health Centre, Victoria, Canada</aff><aff id="aff2">
<label><sup>2</sup></label>University of Victoria, Victoria, Canada</aff><aff id="aff3">
<label><sup>3</sup></label>University of British Columbia, British Columbia, Canada</aff><author-notes><corresp id="cor1">Correspondence: Marion Selfridge, Cool Aid Community Health Centre, 713 Johnson St, V8W 1M8, Victoria, British Columbia, Canada. E-mail: <email>mselfridge@coolaid.org</email></corresp></author-notes><pub-date publication-format="electronic" date-type="preprint"><day>31</day><month>1</month><year>2024</year></pub-date><pub-date publication-format="electronic" date-type="collection"><month>5</month><year>2024</year><string-date>May 2024</string-date></pub-date><pub-date publication-format="electronic" date-type="pub"><day>08</day><month>5</month><year>2024</year></pub-date><volume>7</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">462259</issue-id><fpage>257</fpage><lpage>272</lpage><history><date date-type="received" iso-8601-date="2023-07-07"><day>07</day><month>7</month><year>2023</year></date><date date-type="rev-recd" iso-8601-date="2023-09-26"><day>26</day><month>9</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-10-01"><day>01</day><month>10</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>08</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>14</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-15 09:25:13.497"><day>15</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; Canadian Association for the Study of the Liver, 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref>https://www.utpjournals.press/about/permissions</ali:license_ref><license-p>This article is free to read to all interested readers, immediately upon publication. For their own personal use, users may read, download, print, search, or link to the full text. Manuscripts published in the <italic toggle="yes">Canadian Liver Journal</italic> are copyrighted to the Canadian Association for the Study of the Liver. Requests for permission to reproduce this article should be made to the University of Toronto Press using the Permission Request Form: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://canlivj.utpjournals.press/policies#_copyright">https://canlivj.utpjournals.press/policies#_copyright</ext-link> or by email: <email>journal.permissions@utpress.utoronto.ca</email>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="canlivj-2023-0016.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="canlivj-2023-0016.pdf"/><abstract><title>Abstract</title><sec><title>Background:</title><p>Canada is currently on target to reach the 2030 WHO goal of HCV elimination. Continued high rates of treatment are required to meet this goal. Novel models such as Tayside, Scotland pharmacy-based HCV screening and treatment have proven successful to engage people who use drugs (PWUD) in HCV therapy with a simplified, task-shifted cascade of care. This study seeks to determine whether these successes can be replicated at community pharmacies in Victoria BC.</p></sec><sec><title>Methods:</title><p>Four pharmacies who work with PWUD and provide opioid agonist therapy were trained to provide consent and perform point-of-care HCV antibody screening. They were supported by study nurse to link to HCV RNA testing when antibody positive patients were identified, with HCV treatment offered to RNA positive participants. Qualitative interviews were conducted with five pharmacy staff to explore experiences and feasibility of pharmacists in HCV care cascade.</p></sec><sec><title>Results:</title><p>Pharmacy staff completed 200 HCV OraQuick tests between October 2020 and June 2022: 65 HCV antibody positive, 29 HCV RNA negative (25 previously treated and 4 self-cleared). Of the 26 RNA positive participants, one is awaiting treatment, 25 people have started treatment, 22 achieving SVR. Although the onset of the COVID-19 pandemic was a fundamental barrier incorporating HCV testing at pharmacies, stigma related to HCV and illicit drug use continues to impact this process.</p></sec><sec><title>Conclusions:</title><p>This innovative pharmacy-based approach found people with limited connection to primary health care to test and treat HCV but requires more training and support to be more widely feasible.</p></sec></abstract><kwd-group><title>Keywords:</title><kwd>DAA</kwd><x xml:space="preserve">; </x><kwd>drug use</kwd><x xml:space="preserve">; </x><kwd>hepatitis C</kwd><x xml:space="preserve">; </x><kwd>micro-elimination</kwd><x xml:space="preserve">; </x><kwd>people who inject drugs</kwd><x xml:space="preserve">; </x><kwd>pharmacy</kwd><x xml:space="preserve">; </x><kwd>PWID</kwd><x xml:space="preserve">; </x><kwd>task shifting</kwd><x xml:space="preserve">; </x><kwd>treatment</kwd></kwd-group><funding-group><award-group><funding-source>Gilead</funding-source><award-id>IN-CA-987-5735</award-id></award-group><funding-statement>Special thanks to Gilead for funding this project: IN-CA-987-5735.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>